Literature DB >> 29476693

Cold ischemia time is an important risk factor for post-liver transplant prolonged length of stay.

Evelyn T Pan1, Dor Yoeli1, N Thao N Galvan1, Michael L Kueht1, Ronald T Cotton1, Christine A O'Mahony1, John A Goss1, Abbas Rana1.   

Abstract

Risk analysis of cold ischemia time (CIT) in liver transplantation has largely focused on patient and graft survival. Posttransplant length of stay is a sensitive marker of morbidity and cost. We hypothesize that CIT is a risk factor for posttransplant prolonged length of stay (PLOS) and aim to conduct an hour-by-hour analysis of CIT and PLOS. We retrospectively reviewed all adult, first-time liver transplants between March 2002 and September 2016 in the United Network for Organ Sharing database. The 67,426 recipients were categorized by hourly CIT increments. Multivariate logistic regression of PLOS (defined as >30 days), CIT groups, and an extensive list of confounding variables was performed. Linear regression between length of stay and CIT as continuous variables was also performed. CIT 1-6 hours was protective against PLOS, whereas CIT >7 hours was associated with increased odds for PLOS. The lowest odds for PLOS were observed with 1-2 hours (odds ratio [OR], 0.65; 95% confidence interval [CI], 0.45-0.92) and 2-3 hours (OR, 0.65; 95% CI, 0.55-0.78) of CIT. OR for PLOS steadily increased with increasing CIT, reaching the greatest odds for PLOS with 13-14 hours (OR, 2.05; 95% CI, 1.57-2.67) and 15-16 hours (OR, 2.06; 95% CI, 1.27-3.33) of CIT. Linear regression revealed a positive correlation between length of stay and CIT with a correlation coefficient of +0.35 (P < 0.001). In conclusion, post-liver transplant length of stay is sensitive to CIT, with a substantial increase in the odds of PLOS observed with nearly every additional hour of cold ischemia. We conclude that CIT should be minimized to protect against the morbidity and cost associated with posttransplant PLOS. Liver Transplantation 24 762-768 2018 AASLD.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 29476693     DOI: 10.1002/lt.25040

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

1.  The Impact of Pre-analytical Quality Initiatives on Cholangiocarcinoma Diagnostics in Thailand.

Authors:  Supinda Koonmee; Sakkarn Sangkhamanon; Piyapharom Intarawichian; Chaiwat Aphivatanasiri; Waritta Kunprom; Prakasit Sa-Ngiamwibool; Suwit Balthaisong; Chitsakul Phuyao; Piya Prajumwongs; Reza Alaghehbandan; Malinee Thanee
Journal:  Front Public Health       Date:  2022-06-10

Review 2.  Advances in machine perfusion, organ preservation, and cryobiology: potential impact on vascularized composite allotransplantation.

Authors:  Laura C Burlage; Shannon N Tessier; Joanna W Etra; Korkut Uygun; Gerald Brandacher
Journal:  Curr Opin Organ Transplant       Date:  2018-10       Impact factor: 2.640

3.  Living Donor Liver Transplantation vs. Split Liver Transplantation Using Left Lateral Segment Grafts in Pediatric Recipients: An Analysis of the UNOS Database.

Authors:  Christina Dalzell; Paola A Vargas; Kyle Soltys; Frank Dipaola; George Mazariegos; Jose Oberholzer; Nicolas Goldaracena
Journal:  Transpl Int       Date:  2022-03-22       Impact factor: 3.782

4.  Development of a Novel Prognostic Nomogram for High Model for End-Stage Liver Disease Score Recipients Following Deceased Donor Liver Transplantation.

Authors:  Mengfan Yang; Abdul Rehman Khan; Di Lu; Xuyong Wei; Wenzhi Shu; Chuanshen Xu; Binhua Pan; Zhisheng Zhou; Rui Wang; Qiang Wei; Beini Cen; Jinzhen Cai; Shusen Zheng; Xiao Xu
Journal:  Front Med (Lausanne)       Date:  2022-03-03

5.  Is a Preservation Solution for Living Donor Liver Transplantation Needed? Adding a New Chapter in LDLT!

Authors:  Abdul Wahab Dogar; Kaleem Ullah; Syed Hasnain Abbas; Azhar Hussain; Abdul Ghaffar; Hafiz Bilal; Azam Shoaib; Bilal Ahmed; Hamid Raza; Ameer Hamza; Abu Bakar Hafeez Bhatti; Subash Gupta; Sylvester M Black; Khalid Mumtaz
Journal:  Transplant Direct       Date:  2022-10-07

6.  Subzero non-frozen preservation of human livers in the supercooled state.

Authors:  Reinier J de Vries; Shannon N Tessier; Peony D Banik; Sonal Nagpal; Stephanie E J Cronin; Sinan Ozer; Ehab O A Hafiz; Thomas M van Gulik; Martin L Yarmush; James F Markmann; Mehmet Toner; Heidi Yeh; Korkut Uygun
Journal:  Nat Protoc       Date:  2020-05-20       Impact factor: 13.491

7.  Early Allograft Dysfunction Increases Hospital Associated Costs After Liver Transplantation-A Propensity Score-Matched Analysis.

Authors:  Simon Moosburner; Igor M Sauer; Frank Förster; Thomas Winklmann; Joseph Maria George Vernon Gassner; Paul V Ritschl; Robert Öllinger; Johann Pratschke; Nathanael Raschzok
Journal:  Hepatol Commun       Date:  2020-12-05

8.  Influence of Preformed Antibodies in Liver Transplantation.

Authors:  Isabel Legaz; Francisco Boix; Manuela López; Rafael Alfaro; José A Galián; Santiago Llorente; Jose A Campillo; Carmen Botella; Pablo Ramírez; Francisco Sánchez-Bueno; José A Pons; María R Moya-Quiles; Alfredo Minguela; Manuel Muro
Journal:  J Clin Med       Date:  2020-03-05       Impact factor: 4.241

9.  Poor outcomes of early recurrent post-transplant bloodstream infection in living-donor liver transplant recipients.

Authors:  Si-Ho Kim; Seok Jun Mun; Jae-Hoon Ko; Kyungmin Huh; Sun Young Cho; Cheol-In Kang; Doo Ryeon Chung; Gyu-Seong Choi; Jong Man Kim; Jae-Won Joh; Kyong Ran Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-21       Impact factor: 3.267

10.  Efficiency of Machine Learning Algorithms for the Determination of Macrovesicular Steatosis in Frozen Sections Stained with Sudan to Evaluate the Quality of the Graft in Liver Transplantation.

Authors:  Fernando Pérez-Sanz; Miriam Riquelme-Pérez; Enrique Martínez-Barba; Jesús de la Peña-Moral; Alejandro Salazar Nicolás; Marina Carpes-Ruiz; Angel Esteban-Gil; María Del Carmen Legaz-García; María Antonia Parreño-González; Pablo Ramírez; Carlos M Martínez
Journal:  Sensors (Basel)       Date:  2021-03-12       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.